Clinical trials: sponsored by Royal Marsden NHS Foundation Trust
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage I
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
This is a single arm, multi-centre, phase II open label study of nivolumab with stereotactic body radiotherapy (SBRT) for early stage non-small cell lung cancer.
- Trial name
- STILE (NCT03383302)
- Testing
- Stereotactic body radiotherapy, Nivolumab
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Cervix Cancer
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer
Locally advanced cervix cancers (stage 1B-IV) are usually treated with radiotherapy, concomitant cisplatin chemotherapy and brachytherapy.
- Trial name
- PAPAYA (NCT03144466)
- Testing
- Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer, Metastasis
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT)…
- Conditions
- Prostate Cancer, Metastasis, Toxicity Due to Radiotherapy, Circulating Tumour DNA
- Trial name
- TRAP (NCT03644303)
- Testing
- SBRT + ADT
- Where
- 7 sites in United Kingdom
- Volunteers
- 86 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma, Cancer
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
The study is a first in man, dose escalation study to evaluate the safety, tolerability and how the drug works in the body in patients with all solid tumours.
- Trial name
- PanRAF (NCT02437227)
- Testing
- CCT3833
- Where
- 2 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Thoracic Tumours
Pembrolizumab and Palliative Radiotherapy in Lung
Lung cancer is the second most common cancer in the UK with around 43,500 new patients diagnosed each year. About 69% of patients are diagnosed with advanced stage disease and at present these patients would be expected to…
- Trial name
- PEAR (NCT02587455)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma
Trial of Pembrolizumab and Radiotherapy in Melanoma
Around 13,000 participants are diagnosed with melanoma in the UK each year and that number is growing quicker than any other cancer.
- Trial name
- PERM (NCT02562625)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma
PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
This study aims to establish whether the combination of pembrolizumab (MK-3475) and conventional cisplatin-based chemoradiotherapy is tolerable and results in acceptable levels of acute and late toxicity in patients with stage IV…
- Trial name
- PEACH (NCT02819752)
- Testing
- Pembrolizumab, Radiotherapy, Chemotherapy
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Soft-tissue Sarcoma
Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma
The objective of this trial is to assess the safety and tolerability of combining compound 451238 and radiotherapy, treating advanced STS.
- Trial name
- NCT03602833
- Testing
- Compound 451238
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Sarcoma
Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Soft tissue sarcomas (STS) are a group of rare mesenchymal neoplasms affecting all ages. STS most commonly present as localised disease but despite surgery and adjuvant treatment more than half of patients will develop recurrent…
- Trial name
- GEMMK (NCT03123276)
- Testing
- Pembrolizumab, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Advanced Malignant Pleural Mesothelioma
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM.
- Trial name
- MESO-PRIME (NCT04166734)
- Testing
- Pembrolizumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Non-small-cell lunG Cancer
PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients
This is a single centre non-randomised open label phase 1 trial of lung SBRT to part of a lung lesion in patients with advanced NSCLC in combination with pembrolizumab.
- Trial name
- PRIMING (NCT03436056)
- Testing
- Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#), Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#), Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Lobular Breast Carcinoma, Gastric Cancer
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
The purpose of this study was to find out how effective the combination of crizotinib and fulvestrant was in shrinking lobular breast cancer tumours.
- Conditions
- Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation
- Trial name
- ROLo (NCT03620643)
- Testing
- Crizotinib Oral Capsule [Xalkori], Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
- Where
- 5 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Infectious Disease, Cancer
Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
People with cancer may be at higher risk of poor outcomes with COVID-19 infection. This observational study aims to describe the clinical course of COVID-19 infection in people with cancer and evaluate the utility of antibody and…
- Conditions
- Infectious Disease, Cancer, Coronavirus Infection
- Trial name
- CARDS (NCT04427280)
- Testing
- Throat/nose swabs, Saliva collection, Blood collection
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Recurrent Oropharynx Carcinoma
Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer
The purpose of this research project is to measure changes in communication, swallowing and quality of life and individual patient priorities which may happen over time in patients with a diagnosis of recurrent head and neck…
- Trial name
- FUNQOLR (NCT04952922)
- Testing
- Treatment for recurrent oropharyngeal cancer (curative/ palliative)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Recurrent Head and Neck Cancer
Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
transoral Robotic surgery for rECurrent tumours of the Upper aerodigestive Tract
- Trial name
- RECUT (NCT04673929)
- Where
- 2 sites in United Kingdom
- Volunteers
- 278 people
- Sponsor
- Royal Marsden NHS Foundation Trust